Author Archives: Forest Ray PhD

Equfina Launched in S. Korea as Add-on for ‘Off’ Periods

Eisai Korea has launched Equfina (safinamide) in South Korea as an add-on therapy to levodopa for people with Parkinson’s disease who are experiencing “off” episodes. Equfina was approved in South Korea last year and this represents the medication’s first launch in Asia outside of Japan. Marketed as Xadago…

Gut Fungi Not Linked to Parkinson’s Development

While scientists continue to shed light on a connection between gut bacteria and Parkinson’s disease, one study has found that gut fungi appear not to contribute to the neurodegenerative disorder. This result might serve as a useful warning against investing in potentially futile anti-fungal treatments for people with…

Patients Report Higher Stress, Telemedicine Use Due to COVID-19

Expanding telemedicine services and their accessibility could support people with Parkinson’s disease through the COVID-19 pandemic and beyond by addressing unmet needs and economic disparities. These are some of the conclusions of a survey conducted by the Parkinson’s Foundation, in collaboration with Columbia University, that revealed key…

Vision Test May Predict Cognitive Decline in Parkinson’s Patients

Visual dysfunction and its underlying brain changes can identify Parkinson’s disease patients at higher risk of cognitive decline, who might benefit most from future clinical trials, according to two new studies. The studies, “Organisational and neuromodulatory underpinnings of structural-functional connectivity decoupling in patients with Parkinson’s disease”…

Dormant Viruses May Cause Parkinson’s

Dormant viruses lying hidden in the nervous system can give rise to Parkinson’s disease, according to a newly-published biological model. The article describing this finding, “How microcompetition with latent viruses can cause α synuclein aggregation, mitochondrial dysfunction, and eventually Parkinson’s disease,” was published in the Journal…

Adamas Aquires Global Rights to Osmolex ER for Motor Symptoms

Adamas Pharmaceuticals has acquired global rights to the Parkinson’s disease medication Osmolex ER (amantadine hydrochloride), used to treat motor symptoms, including those caused by other therapies. The purchase, worth $7.5 million, was part of a settlement agreement with the medicine’s developer, Osmotica Pharmaceutical US, according to a…

Ask an expert survey graphic

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums